

EHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias

Dates: April 25-26, 2025

Location: Mercure Hotel MOA, Berlin, Germany

Chairs: Konstanze Döhner, Paresh Vyas, and Maria Teresa Voso

Collaborating SWG: EHA Specialized Working Group on Acute Myeloid Leukemia

The meeting will provide a thorough update on susceptibility factors to sAML, including germ-line and acquired molecular lesions, as well as the role of the bone marrow microenvironment. In addition, clinically important aspects such as sAML following childhood malignancies, leukemogenic effects of drugs as well as prevention/surveillance strategies will be discussed. Finally, the meeting will also focus on special situations including sAML following gene therapy, CAR-T cell therapy, and AML of donor origin in the context of allogeneic stem cell transplantation.

Major experts in the molecular characterization of sAML and the translational consequences in disease diagnosis, management, and treatment will join the meeting and be part of an intensive scientific exchange. With this meeting, we would particularly encourage young researchers and clinician scientists to present their data on sAML in one of the abstract or poster sessions.

The meeting will cover the following topics:

- Germ-line and acquired predisposition to sAML
- Clonal progression from other myeloid diseases (BM-failure s., MDS, MPN)
- sAML development as a result of cancer treatment (after chemotherapy, CAR-T, gene therapy)
- Genetic characteristics of sAML
- Treatment of sAML
- Allogeneic stem cell transplantation (donor-derived sAML)

Friday, April 25

09:00 - 09:15 **Opening & Welcome**

09:15 - 10:00 **Keynote: Classification and epidemiology of secondary and therapy-related leukemias**

- Coleman Lindsley (United States)

10:00 - 10:30 Coffee break

10:30 - 11:50 **Session 1: Susceptibility and mechanisms of secondary leukemogenesis**

- BM-failure syndromes
Carmelo Gurnari (Italy)
- DDX41 and other susceptibility genes
Marie Sebert (France)
- TP53 and other classifier mutations
Andrew Wei (Australia)

11:50 - 12:50 **Oral Abstracts Session 1**

12:50 - 14:20 Lunch break

13:20 - 14:20 **Satellite Symposium**

Breakout Sessions

14:20 - 15:40 **Breakout A: Drugs and diseases in th-related AML**

- Solid tumors and PARPi
Elisabetta Todisco (Italy)
- Hematologic malignancies (topo-II inhibitors, lenalidomide, autologous transplantation)
Sylvain Garciaz (France)
- Secondary leukemias with recurrent genetic abnormalities
Coleman Lindsley (United States)

14:20 - 15: 40 **Breakout B**

- Quantitative dynamics for transformation of MDS to AML
Verena Korber (United Kingdom)
- AML microenvironment
Dominique Bonnet (United Kingdom)
- Modelling secondary AML using human iduced pluripotent stem cells
Eirini Papapetrou (United States)

15:40 - 16:00 Coffee break

16:00 - 17:20 Session 2: Mechanisms of clonal progression

- CHIP and clinical management
Kirsten Grønbæk (Denmark)
- Clonal trajectories from normal hemopoiesis to clonal hemopoiesis (CH and CCUS) to MDS and MPD and then to AML
Coleman Lindsley (United States)
- Progressive immune remodelling as hemopoiesis changes over time from normal hemopoiesis to sAML
Shahram Kordasti (United Kingdom)

17:20 - 18:20 Satellite Symposium**18:20 - 19:20 Welcome reception & poster walk**

Saturday, April 26

08:30 - 09:15 **Keynote: Complex karyotype in sAML**

- Christoph Plass (Germany)

09:15 - 10:35 **Session 3: Special situations**

- sAML in childhood (including after gene-therapy)
Pietro Merli (Italy)
- After CAR-T cell treatment
Michael Hudecek (Germany)
- Donor-derived leukemias after HSCT
Daniel Wiseman (United Kingdom)

10:35 - 11:00 Coffee break

11:00 - 12:00 **Oral Abstract Session 2**

12:00 - 13:00 **Session 4: Treatment**

- Conventional CHT
Christian Recher (France)
- Semi-intensive treatment
Andrew Wei (Australia)
- Transplant-related issues in sAML
Jorge Sierra (Spain)

13:00 - 13:15 **Takeaways & Closing**

13:15 - 14:00 Farewell lunch